|
|
|
|
Conference:
Day one
25 June 8.30am - 5:30pm
Day two
26 June 8.30am - 5:30pm
|
|
|
|
Our event partners
|
Astellas Pharma
|
|
 With revenues exceeding $1.7Bn and approximately 1,900 employees, Astellas Pharma US drives development efforts that offer innovative treatment of unmet medical needs and advancement of good health globally. Astellas is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. In the U.S., Astellas markets products in the areas of immunology, urology, anti-infectives, cardiovascular and dermatology.
Further expanding upon internal development efforts to enter the oncology space, in 2007 Astellas Pharma Inc acquired Agensys, a biotechnology company specializing in therapeutic antibody research and development. Agensys was founded by an experienced executive team, and renowned UCLA oncologists and cancer scientists to explore drug targets and therapeutic antibody development. By applying differential gene expression technology to human tissues Agensys has identified 30 proprietary targets in 14 cancer types.
Astellas is committed to becoming one of the top ten, global pharmaceutical companies by 2015. Critical to this success will be our employees. As such, Astellas is equally committed to being the employer of choice within the pharmaceutical industry. Offering first class benefits, an outstanding work environment and challenging development opportunities at every turn, Astellas is the place to make a difference from day one. www.us.astellas.com
|
|
|
|
|
Professor Sir Michael Rawlins
Chairman
NICE
Dr Giulio Draetta
Head, Worldwide Basic Oncology Research
Merck & Co
Dr Christian Jacques
Executive Director, Oncology
Novartis
Dr Roy Baynes
VP, Global Development, Oncology Supportive Care
Amgen
Selma Schimmel
Founder & Chief Executive Officer
Vital Options International
|
|
|
|
|
|
|
|
|
|
